Verastem Oncology Announces Appointment of John Hayslip, M.D., to Chief Medical Officer - Seite 3

Other risks and uncertainties include those identified under the heading “Risk Factors” in the Company’s Annual Report on Form 10-K for the year ended December 31, 2023, as filed with the Securities and Exchange Commission (SEC) on March 14, 2024, and in any subsequent filings with the SEC. The forward-looking statements contained in this press release reflect Verastem Oncology’s views as of the date hereof, and the Company does not assume and specifically disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20240418758500/en/

The Verastem Stock at the time of publication of the news with a raise of 0,00 % to 1,020USD on Nasdaq stock exchange (01. Juni 2023, 02:00 Uhr).